Ashley Ghiaseddin

A Phase 3, Multiregional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma

Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas

Overcoming Immune Checkpoint Blockade Resistance in Glioblastoma with a Novel Stem Cell Biotherapeutic

A Phase 2, multicenter, clinical study to evaluate the efficacy and safety of safusidenib erbumine in patients with isocitrate dehydrogenase 1 (IDH1)-mutant glioma

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant with Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant with Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58)

Adoptive Cellular Therapy Targeting Recurrent/Progressive Oligodendroglioma

Image analysis for ATTAC-II: A Phase II Randomized, Blinded, and Placebo-controlled Trial of CMV RNA-pulsed Dendritic Cells with Tetanus-Diphtheria Toxoid Vaccine in Patients with Newly-Diagnosed Glioblastoma

Neosoma Brain Tumor Image Analysis and Workflow Software ###

Overcoming the blood-brain barrier with nanoparticle vaccines against gliomas

Clinical Development of CAR T Cell Therapy Targeting CD70 in Primary Glioblastoma

CTOA

Phase 2, Single Arm, Historically Controlled Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients with Newly Diagnosed Glioblastoma

A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Eflornithine with Lomustine Compared to Lomustine Alone in Patients with Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

A PHASE I OPEN LABEL, RANDOMIZED, CONTROLLED PHASE II STUDY TESTING THE SAFETY, TOXICITIES, AND EFFICACY OF MK-3475...